Compare GDDY & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDDY | RDY |
|---|---|---|
| Founded | 1997 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 9.9B |
| IPO Year | 2014 | 2001 |
| Metric | GDDY | RDY |
|---|---|---|
| Price | $103.83 | $11.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $136.44 | $16.90 |
| AVG Volume (30 Days) | 1.6M | ★ 2.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.94 | $7.72 |
| Revenue Next Year | $6.10 | $3.50 |
| P/E Ratio | $28.59 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.59 | $11.36 |
| 52 Week High | $148.19 | $15.67 |
| Indicator | GDDY | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 42.12 |
| Support Level | $81.16 | $11.58 |
| Resistance Level | $101.99 | $12.38 |
| Average True Range (ATR) | 3.30 | 0.16 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 63.82 | 37.59 |
GoDaddy Inc provides digital solutions and services for entrepreneurs, small businesses, individuals, organizations, developers, designers, and domain investors. It offers tools intended to support business creation and management through an integrated service platform. The company operates through two segments: Applications and Commerce (A&C) and Core Platform (Core). The majority of the company's revenue is derived from the Core Platform segment, which consists of sales of domain registrations and renewals, aftermarket domain sales, website hosting products and website security products. Geographically, it generates the maximum revenue from the United States.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.